Search results
Showing 991 to 1005 of 1364 results for social care
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
Discontinued Reference number: GID-MT563
In development Reference number: GID-TA10745 Expected publication date: 17 July 2024
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Discontinued Reference number: GID-TA10512
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued Reference number: GID-TA10321
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
In development Reference number: GID-TA11214 Expected publication date: TBC
Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]
Discontinued Reference number: GID-TA10047
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)
Discontinued Reference number: GID-MT536
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325